STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNDM
  4. [Form 4] TANDEM DIABETES CARE INC Insider Trading Activity

Tandem Diabetes (TNDM) EVP reports RSU vesting and updated holdings

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Tandem Diabetes Care Inc. executive vice president and chief commercial officer Mark D. Novara reported equity activity involving company stock. On 12/15/2025, 7,415 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units granted under the 2023 Long-Term Incentive Plan. To cover tax withholding on this vesting, 3,843 shares were withheld by the company at a price of $22.11 per share, and no shares were sold into the market.

After these transactions, Novara directly beneficially owned 35,956 shares of Tandem Diabetes Care common stock and 29,658 restricted stock units, each representing a contingent right to receive one share of common stock or cash, in accordance with the plan’s terms.

Positive

  • None.

Negative

  • None.
Insider Novara Mark David
Role EVP & CHIEF COMMERCIAL OFFICER
Type Security Shares Price Value
Exercise Restricted Stock Unit 7,415 $0.00 --
Exercise Common Stock 7,415 $0.00 --
Tax Withholding Common Stock 3,843 $22.11 $85K
Holdings After Transaction: Restricted Stock Unit — 29,658 shares (Direct); Common Stock — 39,799 shares (Direct)
Footnotes (1)
  1. Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Novara Mark David
(Last) (First) (Middle)
12400 HIGH BLUFF DRIVE
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & CHIEF COMMERCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/15/2025 M 7,415 A $0 39,799 D
Common Stock 12/15/2025 F(1) 3,843 D $22.11 35,956 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit(2) (3) 12/15/2025 M 7,415 (4) (4) Common Stock 7,415 $0 29,658 D
Explanation of Responses:
1. Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
2. Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
Remarks:
/s/ Shannon M. Hansen, Attorney-in-Fact for Mark D. Novara 12/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TNDM executive Mark D. Novara report?

Mark D. Novara reported the vesting and settlement of 7,415 restricted stock units into Tandem Diabetes Care common stock on 12/15/2025, at an exercise price of $0.

How many Tandem Diabetes Care (TNDM) shares were withheld for taxes?

The company withheld 3,843 shares of common stock at $22.11 per share to satisfy tax withholding requirements related to the RSU vesting. No shares were sold.

How many Tandem Diabetes Care (TNDM) shares does Mark D. Novara own after this Form 4?

Following the reported transactions, Mark D. Novara directly beneficially owned 35,956 shares of Tandem Diabetes Care common stock.

How many restricted stock units does the TNDM executive still hold?

After the vesting event, Mark D. Novara held 29,658 restricted stock units, each representing a contingent right to receive one share of common stock or cash.

What plan governs the reported Tandem Diabetes Care (TNDM) RSU award?

The restricted stock units were awarded on December 15, 2023 under the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended.

How do the reported TNDM RSUs vest for the executive?

The RSUs vest as to 33% of the total shares on 12/15/2024, with the remaining shares vesting in eight equal quarterly installments thereafter.